TipRanks
Advertisement
Advertisement

BHVN Stock Latest News

Biohaven Rated Buy on Opakalim’s KV7 Safety Edge and Differentiated Tolerability Profile
RatingsBiohaven Rated Buy on Opakalim’s KV7 Safety Edge and Differentiated Tolerability Profile
8d ago
BHVN
Citi views Xenon study pause as positive for Biohaven
PremiumThe Fly
Citi views Xenon study pause as positive for Biohaven
8d ago
BHVN
XENE
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
PremiumThe Fly
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
16d ago
BHVN
Biohaven: Clinical Hold on Opakalim Balances Risks and Rewards, Supporting Unchanged $10 Price Target and Neutral Rating
PremiumRatings
Biohaven: Clinical Hold on Opakalim Balances Risks and Rewards, Supporting Unchanged $10 Price Target and Neutral Rating
16d ago
BHVN
Biohaven falls -14.0%
PremiumThe Fly
Biohaven falls -14.0%
16d ago
BHVN
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
PremiumThe FlyImpact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
16d ago
BHVN
Biohaven down 15% after FDA puts partial clinical hold on BHV-7000 program
Premium
The Fly
Biohaven down 15% after FDA puts partial clinical hold on BHV-7000 program
16d ago
BHVN
Biohaven falls -15.3%
Premium
The Fly
Biohaven falls -15.3%
16d ago
BHVN
Biohaven faces partial FDA hold on BHV-7000 program
PremiumCompany Announcements
Biohaven faces partial FDA hold on BHV-7000 program
16d ago
8K
BHVN
Biohaven downgraded to Sector Perform from Outperform at RBC Capital
PremiumThe Fly
Biohaven downgraded to Sector Perform from Outperform at RBC Capital
18d ago
BHVN
Biohaven: Opakalim Deal Seen as Strategically Neutral; Sell Rating Reiterated with Unchanged $11 Price Target
PremiumRatings
Biohaven: Opakalim Deal Seen as Strategically Neutral; Sell Rating Reiterated with Unchanged $11 Price Target
1M ago
BHVN
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
PremiumThe Fly
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
1M ago
BHVN
XENE
Biohaven rises 10.8%
PremiumThe FlyBiohaven rises 10.8%
1M ago
BHVN
Biohaven price target lowered to $30 from $50 at Raymond James
Premium
The Fly
Biohaven price target lowered to $30 from $50 at Raymond James
1M ago
BHVN
Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals
Premium
Company Announcements
Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals
1M ago
8K
BHVN
Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact
PremiumThe Fly
Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact
1M ago
BHVN
Biohaven price target raised to $19 from $18 at Morgan Stanley
PremiumThe Fly
Biohaven price target raised to $19 from $18 at Morgan Stanley
1M ago
BHVN
Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price Target
PremiumRatings
Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price Target
1M ago
BHVN
Biohaven price target raised to $23 from $22 at RBC Capital
PremiumThe Fly
Biohaven price target raised to $23 from $22 at RBC Capital
2M ago
BHVN
Biohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price Target
PremiumRatingsBiohaven: Broad Late-Stage Pipeline Supports Buy Rating and Unchanged $21 Price Target
2M ago
BHVN
Biohaven reports Q2 EPS (78c), consensus (61c)
Premium
The Fly
Biohaven reports Q2 EPS (78c), consensus (61c)
2M ago
BHVN
Biohaven Appoints John Yetimoglu to Board of Directors
Premium
Company Announcements
Biohaven Appoints John Yetimoglu to Board of Directors
2M ago
8K
BHVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >